$TOVX
Theriva Biologics, Inc. Stock $tovx

$tovx Overview Financials Valuation SEC Filings Company Website

2016 Q2 Form 10-Q Financial Statement

#000114420416116282 Filed on August 03, 2016

Income Statement

Concept	2016 Q2	2015 Q4	2015 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.150M	$2.540M	$2.220M
YoY Change	-3.15%	36.56%	22.65%
% of Gross Profit
Research & Development	$7.164M	$8.860M	$7.508M
YoY Change	-4.58%	69.08%	164.65%
% of Gross Profit
Depreciation & Amortization	$20.00K	$30.00K	$10.00K
YoY Change	100.0%	200.0%	0.0%
% of Gross Profit
Operating Expenses	$9.311M	$11.39M	$9.730M
YoY Change	-4.31%	60.42%	109.2%
Operating Profit	-$9.311M		-$9.730M
YoY Change	-4.31%		109.2%
Interest Expense	$30.00K	$0.00	$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net	$3.547M	$100.0K	-$3.893M
YoY Change	-191.11%	-83.87%	-4197.89%
Pretax Income	-$9.311M	-$11.39M	-$9.730M
YoY Change	-4.31%	60.44%	109.2%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$5.764M	-$11.30M	-$13.62M
YoY Change	-57.69%	74.32%	199.01%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.06	-$0.12	-$0.19
Diluted Earnings Per Share	-$0.10	-$0.12	-$0.19
COMMON SHARES
Basic Shares Outstanding	91.02M shares	90.81M shares	72.74M shares
Diluted Shares Outstanding	93.93M shares	90.81M shares	72.74M shares

Balance Sheet

Concept	2016 Q2	2015 Q4	2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$10.05M	$20.82M	$4.760M
YoY Change	111.13%	18.77%	-39.29%
Cash & Equivalents	$10.05M	$20.82M	$4.757M
Short-Term Investments
Other Short-Term Assets	$5.774M	$0.00	$6.955M
YoY Change	-16.98%	-100.0%	400.72%
Inventory
Prepaid Expenses		$208.0K	$315.0K
Receivables
Other Receivables
Total Short-Term Assets	$15.82M	$30.34M	$11.71M
YoY Change	35.1%	59.06%	26.84%
LONG-TERM ASSETS
Property, Plant & Equipment	$480.0K	$494.0K	$110.0K
YoY Change	336.36%	660.0%	115.69%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$30.00K	$10.00K	$20.00K
YoY Change	50.0%	0.0%	100.0%
Total Long-Term Assets	$510.0K	$513.0K	$130.0K
YoY Change	292.31%	622.54%	128.07%
TOTAL ASSETS
Total Short-Term Assets	$15.82M	$30.34M	$11.71M
Total Long-Term Assets	$510.0K	$513.0K	$130.0K
Total Assets	$16.33M	$30.85M	$11.84M
YoY Change	37.92%	61.15%	27.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.560M	$4.410M	$8.690M
YoY Change	-47.53%	342.77%	705.38%
Accrued Expenses	$3.020M	$297.0K	$2.010M
YoY Change	50.25%	-77.12%	1213.73%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$15.17M	$15.58M	$25.50M
YoY Change	-40.51%	62.44%	1969.81%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$230.0K	$270.0K
YoY Change
Total Long-Term Liabilities	$230.0K	$270.0K	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.17M	$15.58M	$25.50M
Total Long-Term Liabilities	$230.0K	$270.0K	$0.00
Total Liabilities	$15.40M	$15.84M	$25.50M
YoY Change	-39.61%	65.23%	1973.17%
SHAREHOLDERS EQUITY
Retained Earnings	-$161.3M
YoY Change
Common Stock	$163.6M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.294M	$16.05M	-$13.66M
YoY Change
Total Liabilities & Shareholders Equity	$16.33M	$30.85M	$11.84M
YoY Change	37.93%	61.15%	27.46%

Cashflow Statement

Concept	2016 Q2	2015 Q4	2015 Q2
OPERATING ACTIVITIES
Net Income	-$5.764M	-$11.30M	-$13.62M
YoY Change	-57.69%	74.32%	199.01%
Depreciation, Depletion And Amortization	$20.00K	$30.00K	$10.00K
YoY Change	100.0%	200.0%	0.0%
Cash From Operating Activities	-$5.860M	-$10.97M	-$7.250M
YoY Change	-19.17%	129.5%	119.7%
INVESTING ACTIVITIES
Capital Expenditures	-$10.00K	-$40.00K	-$40.00K
YoY Change	-75.0%	300.0%	100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$10.00K	-$40.00K	-$40.00K
YoY Change	-75.0%	300.0%	100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	810.0K	20.00K	0.000
YoY Change		-99.89%
NET CHANGE
Cash From Operating Activities	-5.860M	-10.97M	-7.250M
Cash From Investing Activities	-10.00K	-40.00K	-40.00K
Cash From Financing Activities	810.0K	20.00K	0.000
Net Change In Cash	-5.060M	-10.99M	-7.290M
YoY Change	-30.59%	-177.18%	119.58%
FREE CASH FLOW
Cash From Operating Activities	-$5.860M	-$10.97M	-$7.250M
Capital Expenditures	-$10.00K	-$40.00K	-$40.00K
Free Cash Flow	-$5.850M	-$10.93M	-$7.210M
YoY Change	-18.86%	129.14%	119.82%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	931000	USD
CY2016Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16331000	USD
CY2015Q4	syn	Warrant Liabilities WarrantLiabilities	10567000	USD
CY2016Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7508000	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7164000	USD
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	9730000	USD
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	9311000	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9519000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	30337000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20818000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	494000	USD
CY2016Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-82000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-13623000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15575000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15319000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	15842000	USD
CY2016Q2	us-gaap	Liabilities Liabilities	15400000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	297000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
CY2016Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-161305000	USD
CY2016Q2	us-gaap	Stockholders Equity StockholdersEquity	2294000	USD
CY2016Q2	us-gaap	Minority Interest MinorityInterest	-1363000	USD
CY2016Q2	syn	Warrant Liabilities WarrantLiabilities	7552000	USD
CY2015Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	277000	USD
CY2016Q2	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1174000	USD
CY2015Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	21000	USD
CY2016Q2	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	50000	USD
CY2015Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	267000	USD
CY2016Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	227000	USD
CY2016Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q2	us-gaap	Common Stock Value CommonStockValue	91000	USD
CY2016Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	163508000	USD
CY2015Q4	syn	Accrued Clinical Consulting Services AccruedClinicalConsultingServices	164000	USD
CY2016Q2	syn	Accrued Clinical Consulting Services AccruedClinicalConsultingServices	1152000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-9730000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-9311000	USD
CY2015Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	2000	USD
CY2016Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	34000	USD
CY2015Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3893000	USD
CY2016Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3547000	USD
CY2015Q2	us-gaap	Profit Loss ProfitLoss	-13623000	USD
CY2016Q2	us-gaap	Profit Loss ProfitLoss	-5764000	USD
CY2015Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-5682000	USD
CY2015Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	3895000	USD
CY2016Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-3513000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3935000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4573000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14002000	USD
	us-gaap	Operating Expenses OperatingExpenses	17937000	USD
	us-gaap	Operating Expenses OperatingExpenses	19892000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-17937000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-19892000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	3000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	35000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8044000	USD
	us-gaap	Profit Loss ProfitLoss	-25981000	USD
	us-gaap	Profit Loss ProfitLoss	-16842000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-315000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	8047000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-3015000	USD
CY2016Q2	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	1800000	USD
CY2015Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	5300000	USD
CY2016Q2	syn	Prepaid Expenses Research And Development PrepaidExpensesResearchAndDevelopment	48000	USD
CY2015Q4	syn	Prepaid Expenses Research And Development PrepaidExpensesResearchAndDevelopment	643000	USD
CY2016Q2	us-gaap	Prepaid Insurance PrepaidInsurance	185000	USD
CY2015Q4	us-gaap	Prepaid Insurance PrepaidInsurance	339000	USD
CY2016Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	718000	USD
CY2015Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	208000	USD
CY2016Q2	us-gaap	Other Assets Current OtherAssetsCurrent	5774000	USD
CY2015Q4	us-gaap	Other Assets Current OtherAssetsCurrent	9519000	USD
CY2016Q2	syn	Prepaid Clinical Research Organizations PrepaidClinicalResearchOrganizations	4823000	USD
CY2015Q4	syn	Prepaid Clinical Research Organizations PrepaidClinicalResearchOrganizations	8329000	USD
CY2016Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	154000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	105000	USD
CY2015Q4	syn	Accrued Manufacturing Costs AccruedManufacturingCosts	0	USD
CY2016Q2	syn	Accrued Manufacturing Costs AccruedManufacturingCosts	203000	USD
CY2015Q4	syn	Accrued Vendor Payments AccruedVendorPayments	133000	USD
CY2016Q2	syn	Accrued Vendor Payments AccruedVendorPayments	486000	USD
CY2016Q2	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	717000	USD
CY2015Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	0	USD
CY2016Q2	us-gaap	Accrued Vacation Current AccruedVacationCurrent	199000	USD
CY2015Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	153000	USD
CY2016Q2	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	258000	USD
CY2015Q4	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	124000	USD
CY2016Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1174000	USD
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	277000	USD
CY2016Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	6800000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	0	shares
	syn	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	50000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
	syn	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	3.75
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	0	shares
CY2015	syn	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod	2448	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	63447	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
CY2015	syn	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue	1.6
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	1.79
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	7974794	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	7908899	shares
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	7858899	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.8
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.79
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.77
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8613413	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7467762	shares
CY2016Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2016Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2016Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	91351068	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	90908234	shares
CY2016Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	91269586	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	90826752	shares
CY2016Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	91015733	shares
CY2015Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	72736829	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	90921243	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	72674650	shares
CY2016Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	93930540	shares
CY2015Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	72736829	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	92651215	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	72674650	shares
CY2016Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5764000	USD
	syn	Stock Issued For Milestone Payments StockIssuedForMilestonePayments	-1350000	USD
	us-gaap	Depreciation Depreciation	57000	USD
	us-gaap	Depreciation Depreciation	19000	USD
	syn	Stock Issued For Milestone Payments StockIssuedForMilestonePayments	0	USD
CY2016Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	636000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	599000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1413000	USD
CY2016Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P7Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P7Y
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2015Q2	syn	Warrant Liabilities WarrantLiabilities	14800000	USD
CY2016Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	2914807	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	1729974	shares
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16842000	USD
CY2016Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2016Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2016Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-9277000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-19857000	USD
CY2015Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13623000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25981000	USD
CY2015Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-13623000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-25981000	USD
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.36
	us-gaap	Share Based Compensation ShareBasedCompensation	1959000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3745000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5407000	USD
	syn	Increase Decrease In Deposits And Other Assets IncreaseDecreaseInDepositsAndOtherAssets	11000	USD
	syn	Increase Decrease In Deposits And Other Assets IncreaseDecreaseInDepositsAndOtherAssets	12000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	143000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	7690000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1543000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	317000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	897000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-144000	USD
	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	-10000	USD
	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	0	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-11534000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-12708000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	45000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	61000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-45000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-61000	USD
	syn	Proceeds From Issuance Of Common Stock For Stock Option And Warrants Exercises ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises	810000	USD
	syn	Proceeds From Issuance Of Common Stock For Stock Option And Warrants Exercises ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises	1000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	810000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	1000	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	-10769000	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	-12768000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17525000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4757000	USD
	us-gaap	Interest Paid InterestPaid	0	USD
	us-gaap	Interest Paid InterestPaid	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD

Files In Submission

Name	View Source	Status
0001144204-16-116282-index-headers.html	Edgar Link	pending
0001144204-16-116282-index.html	Edgar Link	pending
0001144204-16-116282.txt	Edgar Link	pending
0001144204-16-116282-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
syn-20160630.xml	Edgar Link	completed
syn-20160630.xsd	Edgar Link	pending
syn-20160630_cal.xml	Edgar Link	unprocessable
syn-20160630_def.xml	Edgar Link	unprocessable
syn-20160630_lab.xml	Edgar Link	unprocessable
syn-20160630_pre.xml	Edgar Link	unprocessable
tpg16.jpg	Edgar Link	pending
v444734_10q.htm	Edgar Link	pending
v444734_ex31-1.htm	Edgar Link	pending
v444734_ex31-2.htm	Edgar Link	pending
v444734_ex32-1.htm	Edgar Link	pending
v444734_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TOVX
Theriva Biologics, Inc. Stock $tovx

2016 Q2 Form 10-Q Financial Statement

#000114420416116282 Filed on August 03, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TOVX Theriva Biologics, Inc. Stock $tovx

2016 Q2 Form 10-Q Financial Statement

#000114420416116282 Filed on August 03, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TOVX
Theriva Biologics, Inc. Stock $tovx